CTI settles with GE
Litigation involving CTI Molecular Imaging and GE has been settled out of court. The lawsuits were initially brought by GE against CTI Molecular Imaging, its PETNET Solutions radiopharmaceuticals unit, and certain employees of CTI Molecular Imaging to
Litigation involving CTI Molecular Imaging and GE has been settled out of court. The lawsuits were initially brought by GE against CTI Molecular Imaging, its PETNET Solutions radiopharmaceuticals unit, and certain employees of CTI Molecular Imaging to prevent these former GE employees from potentially disclosing or using GE confidential information. The staff had left GE and joined CTI or PETNET before the litigation was initiated. CTI Molecular Imaging announced that the parties worked together to ensure that sufficient safeguards were in place to prevent potential disclosure of GE confidential information and further disputes. CTI Molecular Imaging will incur no charges in connection with the settlement.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
